scPharmaceuticals Inc. (SCPH)

scPharmaceuticals Inc. (SCPH) Healthcare & Pipeline Overview

scPharmaceuticals Inc. is a biotechnology company focused on developing and commercializing innovative pharmaceutical products, primarily FUROSCIX, an on-body infusor-delivered furosemide for heart failure congestion. The company also maintains a pipeline of antibiotic candidates, aiming to address critical unmet needs in cardiovascular and infectious disease management through novel drug delivery solutions.

What Is the Investment Thesis for SCPH?

scPharmaceuticals Inc. presents an investment thesis centered on the potential commercialization and market adoption of its lead product candidate, FUROSCIX, for heart failure congestion. With a gross margin of 68.8%, the company demonstrates strong potential profitability on its products once market penetration is achieved. The on-body infusor delivery system for FUROSCIX offers a differentiated value proposition by potentially enabling outpatient treatment, reducing hospital readmissions, and lowering overall healthcare expenditures for heart failure patients. This innovative delivery mechanism could drive significant market share in the substantial heart failure treatment landscape. Furthermore, the company's pipeline, including scCeftriaxone and scCarbapenem, represents additional long-term growth catalysts, targeting broad and critical infectious disease markets. While the current profit margin stands at -141.7%, typical for a development-stage biotech, successful regulatory approvals and commercial launches of these products are crucial for achieving profitability. The development agreement with West Pharmaceutical Services for the SmartDose device further strengthens its drug delivery platform. Key risks include regulatory hurdles, market acceptance of new delivery methods, and intense competition within both cardiovascular and antibiotic therapeutic areas.

Based on FMP financials and quantitative analysis

SCPH Key Highlights

• Market capitalization stands at $0.30 billion, reflecting its current valuation as a development-stage biotechnology company.
• Gross margin of 68.8% indicates strong potential profitability on product sales once commercialization scales, showcasing efficient cost management relative to revenue.
• Profit margin of -141.7% highlights the company's current status as a pre-profitability entity, typical for biotechnology firms heavily investing in R&D and product development.
• A Beta of 0.30 suggests lower volatility compared to the broader market, potentially appealing to investors seeking more stable equity exposure within the biotechnology sector.
• The company currently offers no dividend yield, consistent with its focus on reinvesting capital into research, development, and commercialization activities.

Who Are SCPH's Competitors?

SCPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SCPH's Key Strengths?

• Lead product candidate FUROSCIX addresses a significant unmet need in heart failure management with a novel delivery method.
• Proprietary on-body infusor technology offers a differentiated and patient-centric treatment option.
• Diverse product pipeline targeting both cardiovascular and critical infectious diseases.
• Strategic development agreement with West Pharmaceutical Services, Inc. for advanced device technology.

What Are SCPH's Weaknesses?

• Currently operating at a significant negative profit margin (-141.7%), typical for a development-stage biotech.
• High reliance on the successful regulatory approval and commercialization of pipeline products.
• Limited commercial revenue streams currently, with primary focus on R&D.
• Unknown market acceptance and adoption rate for the on-body infusor technology.

What Could Drive SCPH Stock Higher?

• Potential regulatory approval milestones for FUROSCIX, paving the way for full commercial launch.
• Initiation or completion of pivotal clinical trials for scCeftriaxone, demonstrating efficacy and safety.
• Advancement of the scCarbapenem program into later-stage clinical development, indicating progress in addressing gram-negative infections.
• Continued development and refinement of the single-use SmartDose device in collaboration with West Pharmaceutical Services, Inc.
• Establishment of commercial partnerships or distribution agreements to support the market entry of FUROSCIX.

What Are the Key Risks for SCPH?

• Financial-distress signal — its Altman Z-Score of -7.29 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Sustained negative profit margin, requiring continued capital raises until commercial products generate substantial revenue.
• Failure to secure or delays in obtaining regulatory approvals for FUROSCIX or its pipeline antibiotic candidates (scCeftriaxone, scCarbapenem).
• Limited market adoption of the on-body infusor technology due to physician or patient preference for traditional administration methods.
• Intense competition from existing therapies and new market entrants in both the heart failure and infectious disease sectors.
• Clinical trial setbacks, including unexpected adverse events or failure to meet primary endpoints, for any of its development programs.

What Are the Growth Opportunities for SCPH?

• Commercialization of FUROSCIX for Heart Failure: The primary growth driver for scPharmaceuticals Inc. is the successful commercialization and market penetration of FUROSCIX. This product, designed for subcutaneous delivery of furosemide via an on-body infusor, targets the significant market of heart failure patients experiencing congestion. The global heart failure drugs market was valued at approximately $5.4 billion in 2023 and is projected to grow, driven by an aging population and increasing prevalence of cardiovascular diseases. By offering a convenient outpatient treatment option, FUROSCIX aims to reduce hospital readmissions and healthcare costs, potentially capturing a substantial share of this market within the next 3-5 years post-launch.
• Expansion into Antibiotic Markets with scCeftriaxone: The development and potential approval of scCeftriaxone represent a significant growth opportunity. This antibiotic targets a broad range of infections caused by both gram-positive and gram-negative organisms, addressing a persistent need for effective antimicrobial treatments. The global antibiotics market was estimated at over $40 billion in 2023 and continues to grow due to the ongoing threat of bacterial infections and antibiotic resistance. Successful clinical trials and regulatory approval could position scCeftriaxone as a valuable addition to the company's portfolio, with market entry potentially within the next 5-7 years, diversifying its revenue streams beyond cardiovascular indications.
• Advancement of scCarbapenem Program: The scCarbapenem program, focusing on antibiotics for gram-negative infections, offers another substantial growth avenue. Gram-negative bacterial infections are increasingly challenging to treat due to rising resistance, creating an urgent demand for new therapeutic options. The market for carbapenem antibiotics alone is a multi-billion dollar segment, with a critical need for novel agents. The successful development and commercialization of scCarbapenem could address a high-unmet medical need, providing a specialized solution for severe infections. This program, while potentially longer-term (7-10 years to market), could unlock significant value by targeting a critical and underserved patient population.
• Leveraging On-Body Infusor Technology for New Indications: The proprietary on-body infusor technology, currently utilized for FUROSCIX, presents a platform growth opportunity. This innovative drug delivery system could be adapted for other medications requiring frequent or precise subcutaneous administration, beyond furosemide. The broader market for drug delivery devices is expanding, driven by patient preference for self-administration and reduced hospital visits. By exploring and developing new drug candidates or reformulating existing ones for delivery via this technology, scPharmaceuticals Inc. could unlock multiple therapeutic areas, creating a sustainable competitive advantage and expanding its addressable market over the long term (5-10+ years).
• Strategic Partnerships and Licensing Agreements: The development agreement with West Pharmaceutical Services for the single-use SmartDose device highlights the potential for strategic collaborations. Such partnerships can accelerate product development, expand market reach, and provide non-dilutive funding. Future agreements, either for co-development, co-commercialization, or out-licensing of its pipeline assets or infusor technology, could provide significant growth. The global pharmaceutical partnering market remains robust, with companies constantly seeking innovative technologies and products to fill their pipelines. These collaborations could generate upfront payments, milestone payments, and royalties, contributing to revenue growth and reducing R&D risk within a 2-5 year timeframe.

What Opportunities Does SCPH Have?

• Large and growing market for heart failure treatments, driven by an aging population.
• Increasing demand for outpatient and home-based care solutions in chronic disease management.
• Significant unmet need for novel antibiotics to combat rising antimicrobial resistance.
• Potential to expand the on-body infusor technology to other therapeutic areas and drug candidates.

What Threats Does SCPH Face?

• Intense competition from established pharmaceutical companies with existing heart failure and antibiotic portfolios.
• Stringent and unpredictable regulatory approval processes for new drug candidates.
• Risk of clinical trial failures or delays impacting product timelines and financial viability.
• Potential for reimbursement challenges or unfavorable pricing pressures for new therapies.

What Are SCPH's Competitive Advantages?

• Proprietary formulation of furosemide (FUROSCIX) specifically designed for subcutaneous delivery.
• Exclusive on-body infusor technology, offering a differentiated drug administration method for home use.
• Development agreement with West Pharmaceutical Services for the SmartDose device, enhancing its delivery platform.
• Specialized pipeline targeting critical unmet needs in both cardiovascular and infectious disease markets.

What Does SCPH Do?

scPharmaceuticals Inc., founded in 2013 and headquartered in Burlington, Massachusetts, is a pharmaceutical company dedicated to the development and commercialization of innovative drug products. The company's strategic focus lies in enhancing patient care through novel delivery mechanisms, particularly for conditions requiring frequent or complex medication administration. Its flagship product candidate, FUROSCIX, represents a significant advancement in the treatment of congestion in patients with heart failure. FUROSCIX is a proprietary formulation of furosemide designed for subcutaneous delivery via an on-body infusor, aiming to provide a convenient and effective alternative to intravenous administration, potentially reducing hospitalizations and healthcare costs associated with fluid overload. This on-body infusor technology is a core differentiator, enabling patients to receive treatment in outpatient settings. Beyond its lead candidate, scPharmaceuticals Inc. maintains a robust product pipeline targeting infectious diseases. This includes scCeftriaxone, an antibiotic being developed to treat a broad spectrum of infections caused by both gram-positive and gram-negative organisms, and the scCarbapenem program, another antibiotic candidate specifically designed for infections caused by gram-negative organisms. These pipeline assets underscore the company's commitment to addressing critical unmet medical needs across various therapeutic areas. To support its innovative delivery platforms, scPharmaceuticals Inc. has established a development agreement with West Pharmaceutical Services, Inc. for the creation of a single-use SmartDose device, further solidifying its position in advanced drug delivery solutions. The company's evolution since 2013 has been marked by a focus on leveraging technology to improve patient outcomes and streamline treatment protocols, positioning it as a key player in the biopharmaceutical landscape.

What Products and Services Does SCPH Offer?

• Develops and commercializes pharmaceutical products for various therapeutic areas.
• Focuses on innovative drug delivery systems, including on-body infusors.
• Lead product candidate, FUROSCIX, treats congestion in heart failure patients via subcutaneous delivery.
• Maintains a pipeline of antibiotic candidates, including scCeftriaxone and scCarbapenem.
• scCeftriaxone targets infections caused by gram-positive and gram-negative organisms.
• scCarbapenem program is designed for infections caused by gram-negative organisms.
• Collaborates with West Pharmaceutical Services, Inc. on the SmartDose device development.
• Aims to improve patient outcomes and reduce healthcare costs through convenient drug administration.

How Does SCPH Make Money?

• Research, develop, and obtain regulatory approval for proprietary pharmaceutical products.
• Commercialize approved products through direct sales or partnerships, generating revenue from product sales.
• Potentially license its drug delivery technology or pipeline assets to other pharmaceutical companies for upfront payments, milestones, and royalties.
• Focus on high-value therapeutic areas where innovative delivery methods can command premium pricing and improve patient adherence.

What Industry Does SCPH Operate In?

scPharmaceuticals Inc. operates within the dynamic and innovation-driven Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by extensive research and development efforts, long regulatory approval cycles, and a high potential for disruptive therapeutic advancements. The broader healthcare market, particularly in cardiovascular and infectious diseases, continues to face challenges such as rising costs, the need for improved patient convenience, and the emergence of antibiotic resistance. scPharmaceuticals Inc. positions itself by developing novel drug formulations and delivery systems, specifically its on-body infusor technology, to address these unmet needs. The competitive landscape includes established pharmaceutical giants with extensive portfolios and numerous smaller biotech firms vying for market share with specialized innovations. The company's focus on subcutaneous delivery for conditions traditionally requiring intravenous administration places it in a niche aiming to capture a segment of the market seeking enhanced outpatient care and reduced hospital burden. Market trends indicate a growing demand for home-based care solutions and therapies that improve patient quality of life, aligning with scPharmaceuticals Inc.'s strategic direction.

Who Are SCPH's Key Customers?

• Patients suffering from congestion due to heart failure, who could benefit from outpatient furosemide administration.
• Healthcare providers, including cardiologists, primary care physicians, and nurses, seeking effective and convenient treatment options.
• Hospitals and healthcare systems aiming to reduce readmission rates and manage costs associated with heart failure exacerbations.
• Infectious disease specialists and hospitals requiring novel antibiotic treatments for resistant bacterial infections.

Company Profile

scPharmaceuticals Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Burlington, US. The company is led by CEO John H. Tucker. SCPH has traded publicly since 2017.

F-Score 2/9Financial Health

scPharmaceuticals Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.29 places it in the distress zone, a signal of elevated financial risk.

ROE 286%Key Financial Metrics

Return on equity for scPharmaceuticals Inc. stands at 285.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -47.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.85 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.4%, the inverse of the P/E and a quick read on earnings relative to price.

SCPH Valuation & Market Position

With a $302.20M market cap, scPharmaceuticals Inc. sits in the small-cap segment of the market. Relative to its peer group, SCPH's quantitative score of 69/100 is roughly in line with the peer average of 76/100.

FY2026 estForward Outlook

Wall Street analysts project scPharmaceuticals Inc. revenue of about $128.1M for fiscal 2026, with EPS near $-0.16. The estimate reflects 3 contributing analysts.

SCPH Financials

SCPH Latest News

SCPH Analyst Consensus

SCPH MoonshotScore

SCPH Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources